Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 21


Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice.

Fabi A, Moscetti L, Ciccarese M, Caramanti M, Salesi N, La Verde N, Russillo M, Generali D, Scandurra G, Vari S, Pacetti U, Cognetti F, Giannarelli D.

Future Oncol. 2015;11(3):431-8. doi: 10.2217/fon.14.271.


Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy.

Fabi A, Russillo M, Ferretti G, Metro G, Nisticò C, Papaldo P, De Vita F, D'Auria G, Vidiri A, Giannarelli D, Cognetti F.

BMC Cancer. 2012 Oct 19;12:482. doi: 10.1186/1471-2407-12-482.


Assessment of PTEN and PI3K status in primary breast cancer and corresponding metastases: is it worthwhile?

Russillo M, Di Benedetto A, Metro G, Ferretti G, Papaldo P, Cognetti F, Mottolese M, Fabi A.

J Clin Oncol. 2011 Jul 10;29(20):2834-5; author reply 2835. doi: 10.1200/JCO.2011.35.1742. Epub 2011 Jun 13. No abstract available.


Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials.

Cuppone F, Bria E, Vaccaro V, Puglisi F, Fabi A, Sperduti I, Carlini P, Milella M, Nisticò C, Russillo M, Papaldo P, Ferretti G, Aapro M, Giannarelli D, Cognetti F.

J Exp Clin Cancer Res. 2011 May 12;30:54. doi: 10.1186/1756-9966-30-54.


PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer.

Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH, Chandarlapaty S, Markman B, Rodriguez O, Guzman M, Rodriguez S, Gili M, Russillo M, Parra JL, Singh S, Arribas J, Rosen N, Baselga J.

Oncogene. 2011 Jun 2;30(22):2547-57. doi: 10.1038/onc.2010.626. Epub 2011 Jan 31.


Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center.

Fabi A, Felici A, Metro G, Mirri A, Bria E, Telera S, Moscetti L, Russillo M, Lanzetta G, Mansueto G, Pace A, Maschio M, Vidiri A, Sperduti I, Cognetti F, Carapella CM.

J Exp Clin Cancer Res. 2011 Jan 18;30:10. doi: 10.1186/1756-9966-30-10.


Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.

Metro G, Foglietta J, Russillo M, Stocchi L, Vidiri A, Giannarelli D, Crinò L, Papaldo P, Mottolese M, Cognetti F, Fabi A, Gori S.

Ann Oncol. 2011 Mar;22(3):625-30. doi: 10.1093/annonc/mdq434. Epub 2010 Aug 19.


Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study.

Fabi A, Metro G, Vidiri A, Lanzetta G, Carosi M, Telera S, Maschio M, Russillo M, Sperduti I, Carapella CM, Cognetti F, Pace A.

J Neurooncol. 2010 Nov;100(2):209-15. doi: 10.1007/s11060-010-0163-3. Epub 2010 Mar 30.


Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme.

Metro G, Fabi A, Mirri MA, Vidiri A, Pace A, Carosi M, Russillo M, Maschio M, Giannarelli D, Pellegrini D, Pompili A, Cognetti F, Carapella CM.

Cancer Chemother Pharmacol. 2010 Jan;65(2):391-7. doi: 10.1007/s00280-009-1155-x. Epub 2009 Oct 22.


Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice.

Fabi A, Russillo M, Metro G, Vidiri A, Di Giovanni S, Cognetti F.

Anticancer Res. 2009 Jul;29(7):2607-10.


Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation.

Fabi A, Metro G, Russillo M, Vidiri A, Carapella CM, Maschio M, Cognetti F, Jandolo B, Mirri MA, Sperduti I, Telera S, Carosi M, Pace A.

BMC Cancer. 2009 Mar 31;9:101. doi: 10.1186/1471-2407-9-101.


Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer: towards optimization of association and schedule.

Metro G, Fabi A, Russillo M, Papaldo P, De Laurentiis M, Ferretti G, Pellegrini D, Nuzzo C, Graziano V, Vici P, Introna M, Felici A, Cognetti F, Carlini P.

Anticancer Res. 2008 Mar-Apr;28(2B):1245-58. Review.


Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II study.

Fabi A, Ciccarese M, Metro G, Savarese A, Giannarelli D, Nuzzo CM, Russillo M, Sperduti I, Carbone I, Bria E, Cognetti F.

Support Care Cancer. 2008 Dec;16(12):1375-80. doi: 10.1007/s00520-008-0438-9. Epub 2008 May 14.


Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies.

Fabi A, Metro G, Ferretti G, Giannarelli D, Di Cosimo S, Papaldo P, Mottolese M, Carlini P, Felici A, Russillo M, Cognetti F.

Breast. 2008 Oct;17(5):499-505. doi: 10.1016/j.breast.2008.03.006. Epub 2008 May 1. Review.


Male breast cancer: 6-year experience.

La Pinta M, Fabi A, Ascarelli A, Ponzani T, Di Carlo V, Scicchitano F, Saputo S, Russillo M, Andrich R.

Minerva Chir. 2008 Apr;63(2):71-8. English, Italian.


[Aromatase inhibitors in advanced breast cancer].

Spinelli GP, Tomao F, Miele E, Pasciuti G, Russillo M, Tomao S.

Recenti Prog Med. 2008 Jan;99(1):34-8. Review. Italian.


Bone of the hands as unusual metastastatic site of renal cell carcinoma.

Salesi N, Russillo M, Marandino F, Ruggeri EM, Metro G, Cognetti F, Fabi A.

J Exp Clin Cancer Res. 2007 Dec;26(4):595-7.


Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer.

Metro G, Sperduti I, Russillo M, Milella M, Cognetti F, Fabi A.

Oncologist. 2007 Dec;12(12):1467-9; author reply 1469-71. doi: 10.1634/theoncologist.12-12-1467. No abstract available.


Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.

Fabi A, Metro G, Papaldo P, Mottolese M, Melucci E, Carlini P, Sperduti I, Russillo M, Gelibter A, Ferretti G, Tomao S, Milella M, Cognetti F.

Cancer Chemother Pharmacol. 2008 Sep;62(4):717-25. Epub 2007 Dec 6.


Trastuzumab in metastatic breast cancer.

Tomao F, Miele E, Spinelli GP, Russillo M, La Ferla G, Tomao S.

Eur J Gynaecol Oncol. 2006;27(3):247-9.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk